{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:42:07Z","timestamp":1786372927805,"version":"build-2736575974"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.2215\/cjn.06900909","type":"journal-article","created":{"date-parts":[[2009,12,10]],"date-time":"2009-12-10T20:40:38Z","timestamp":1260477638000},"page":"371-378","source":"Crossref","is-referenced-by-count":20,"title":["Enzyme Replacement Therapy and Fabry Nephropathy"],"prefix":"10.2215","volume":"5","author":[{"given":"David G.","family":"Warnock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Daina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Remuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-34-20230601","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/ki.1978.32","article-title":"Early renal changes in hemizygous and heterozygous patients with Fabry's disease","volume":"13","author":"Gubler","year":"1978","journal-title":"Kidney Int"},{"key":"R2-34-20230601","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1023\/A:1012423924648","article-title":"Renal pathological changes in Fabry disease","volume":"24","author":"Sessa","year":"2001","journal-title":"J Inherit Metab Dis"},{"key":"R3-34-20230601","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","article-title":"Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy.","volume":"62","author":"Thurberg","year":"2002","journal-title":"Kidney Int"},{"key":"R4-34-20230601","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1053\/j.ajkd.2007.12.032","article-title":"Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria","volume":"51","author":"Tondel","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"R5-34-20230601","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00428-008-0653-2","article-title":"Kidney biopsy findings in heterozygous Fabry disease females with early nephropathy","volume":"453","author":"Valbuena","year":"2008","journal-title":"Virchows Arch"},{"key":"R7-34-20230601","doi-asserted-by":"crossref","first-page":"S134","DOI":"10.1097\/01.ASN.0000016684.07368.75","article-title":"Renal pathology in Fabry disease","volume":"13","author":"Alroy","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"R9-34-20230601","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jmg.38.11.750","article-title":"Anderson-Fabry disease: Clinical manifestations and impact of disease in a cohort of 98 hemizygous males","volume":"38","author":"MacDermot","year":"2001","journal-title":"J Med Genet"},{"key":"R10-34-20230601","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","article-title":"Fabry disease: Progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy","volume":"24","author":"Schiffmann","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"R11-34-20230601","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1093\/ndt\/gfm848","article-title":"Nephropathy in males and females with Fabry disease: Cross-sectional description of patients before treatment with enzyme replacement therapy","volume":"23","author":"Ortiz","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"R12-34-20230601","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: A randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"R13-34-20230601","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1086\/318809","article-title":"A phase 1\/2 clinical trial of enzyme replacement in Fabry disease: Pharmacokinetic, substrate clearance, and safety studies","volume":"68","author":"Eng","year":"2001","journal-title":"Am J Hum Genet"},{"key":"R14-34-20230601","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: A randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann Intern Med"},{"key":"R15-34-20230601","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1681\/ASN.2006111263","article-title":"Weekly enzyme replacement therapy may slow decline of renal function in Fabry patients who are on long-term biweekly dosing","volume":"18","author":"Schiffmann","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R16-34-20230601","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00041552-200503000-00002","article-title":"Fabry disease: Diagnosis and management, with emphasis on the renal manifestations","volume":"14","author":"Warnock","year":"2005","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"R17-34-20230601","first-page":"1","article-title":"Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease","volume":"2","author":"Fervenza","year":"2008","journal-title":"Biologics"},{"key":"R18-34-20230601","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1159\/000168482","article-title":"Agalsidase alfa slows the decline in renal function in patients with Fabry disease","volume":"29","author":"Feriozzi","year":"2009","journal-title":"Am J Nephrol"},{"key":"R19-34-20230601","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1681\/ASN.2008080870","article-title":"Agalsidase alfa and kidney dysfunction in Fabry disease","volume":"20","author":"West","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R20-34-20230601","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1056\/NEJMcp013462","article-title":"Clinical practice: Nondiabetic kidney disease","volume":"347","author":"Levey","year":"2002","journal-title":"N Engl J Med"},{"key":"R21-34-20230601","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease","volume":"18","author":"Germain","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R22-34-20230601","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMra054415","article-title":"Assessing kidney function: Measured and estimated glomerular filtration rate","volume":"354","author":"Stevens","year":"2006","journal-title":"N Engl J Med"},{"key":"R23-34-20230601","first-page":"77","article-title":"Enzyme replacement therapy and renal function in 201 patients with Fabry disease","volume":"66","author":"Schwarting","year":"2006","journal-title":"Clin Nephrol"},{"key":"R24-34-20230601","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/sj.ki.5000208","article-title":"Clinical benefit of enzyme replacement therapy in Fabry disease","volume":"69","author":"Breunig","year":"2006","journal-title":"Kidney Int"},{"key":"R25-34-20230601","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/S0140-6736(00)04728-0","article-title":"Progression, remission, regression of chronic renal diseases","volume":"357","author":"Ruggenenti","year":"2001","journal-title":"Lancet"},{"key":"R26-34-20230601","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1001\/archinte.165.8.947","article-title":"The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: Results of the African American Study of Kidney Disease and Hypertension","volume":"165","author":"Lea","year":"2005","journal-title":"Arch Intern Med"},{"key":"R27-34-20230601","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1046\/j.1523-1755.2003.00033.x","article-title":"Retarding progression of chronic renal disease: The neglected issue of residual proteinuria","volume":"63","author":"Ruggenenti","year":"2003","journal-title":"Kidney Int"},{"key":"R28-34-20230601","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1681\/ASN.2007090970","article-title":"Role of remission clinics in the longitudinal treatment of CKD","volume":"19","author":"Ruggenenti","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"R29-34-20230601","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1681\/ASN.2006121400","article-title":"Antiproteinuric therapy and Fabry nephropathy: Sustained reduction in proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta","volume":"18","author":"Tahir","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R30-34-20230601","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfi152","article-title":"Long-term therapy with agalsidase alfa for Fabry disease: Safety and effects on renal function in a home infusion setting","volume":"21","author":"Schiffmann","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"R32-34-20230601","doi-asserted-by":"crossref","first-page":"360","DOI":"10.2215\/CJN.06090809","article-title":"Biomarkers of Fabry disease nephropathy","volume":"5","author":"Schiffmann","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"R34-34-20230601","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"R35-34-20230601","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with neuropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"R36-34-20230601","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1056\/NEJM200109203451209","article-title":"Prevention of end-stage renal disease due to type 2 diabetes","volume":"345","author":"Hofstetter","year":"2001","journal-title":"N Engl J Med"},{"key":"R38-34-20230601","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1172\/JCI27699","article-title":"Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes","volume":"116","author":"Remuzzi","year":"2006","journal-title":"J Clin Invest"},{"key":"R39-34-20230601","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/ncpneph0806","article-title":"Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults","volume":"4","author":"Ortiz","year":"2008","journal-title":"Nat Clin Pract Nephrol"},{"key":"R40-34-20230601","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","article-title":"Fabry disease: Guidelines for the evaluation and management of multi-organ system involvement","volume":"8","author":"Eng","year":"2006","journal-title":"Genet Med"},{"key":"R41-34-20230601","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"R42-34-20230601","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.2215\/CJN.01340209","article-title":"Mineralocorticoid receptor blockers and chronic kidney disease","volume":"4","author":"Jain","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R43-34-20230601","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1681\/ASN.2006101081","article-title":"Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease.","volume":"18","author":"Kent","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R44-34-20230601","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"key":"R46-34-20230601","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.amjhyper.2006.01.011","article-title":"Prevalence of uncontrolled hypertension in patients with Fabry disease","volume":"19","author":"Kleinert","year":"2006","journal-title":"Am J Hypertens"},{"key":"R47-34-20230601","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/archinte.160.5.685","article-title":"Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: Is this a cause for concern?","volume":"160","author":"Bakris","year":"2000","journal-title":"Arch Intern Med"},{"key":"R48-34-20230601","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ymgme.2008.03.003","article-title":"Treatment of Fabry disease with different dosing regimens of agalsidase: Effects on antibody formation and GL-3","volume":"94","author":"Vedder","year":"2008","journal-title":"Mol Genet Metab"},{"key":"R49-34-20230601","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/nbt.1484","article-title":"Neutralizing antibodies to therapeutic enzymes: Considerations for testing, prevention and treatment","volume":"26","author":"Wang","year":"2008","journal-title":"Nat Biotechnol"},{"key":"R50-34-20230601","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/08035320510028111","article-title":"Is globotriaosylceramide a useful biomarker in Fabry disease?","volume":"94","author":"Young","year":"2005","journal-title":"Acta Paediatr Suppl"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201002000-00034","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:39:16Z","timestamp":1786369156000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201002000-00034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.06900909","relation":{},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2010,2]]}}}